Skip to content

Regulatory Navigation

Regulatory Strategy for Early-Stage Therapeutics

An early regulatory strategy sets out the pathway a product is likely to follow, the evidence each step will need, and when to talk with regulators. For an early company it shapes the research plan, the budget and the story told to investors long before any submission.

Two scientists in safety glasses check notes on a clipboard.

Why Strategy Comes Early

The pathway affects which studies are needed, how large trials must be, and how long development takes. Choices made in early research, such as the models used or the way materials are made, can make later steps easier or harder.

The Elements of a Plan

Product classification and likely pathway in each target market, including EMA and other global pathways; programs and designations that may apply; the evidence expected at each milestone; pre-submission meetings and what to ask in them; and the clinical trial design questions that follow.

Regulatory Milestones as Business Milestones

Investors read regulatory milestones as reductions in risk. We help teams plan the sequence, prepare for agency meetings, and connect each milestone to the funding and partnerships it supports.

Common Questions

  • When should a startup first meet with regulators?

    Often once there is enough preclinical data to ask specific questions about the development plan. Well-prepared pre-submission meetings can save time and studies later.

  • Does Intertwine Bio work on pathways outside the United States?

    Yes. Regulatory navigation includes EMA and global market pathways as well as planning for the United States.

Related Services

Two scientists compare results on a clipboard by a window.

Get Started

Ready to Transform Your Science into a Company?

We partner with founders and research teams committed to bringing breakthrough science to market.